Dipartimento di Biotecnologie e Scienze Molecolari, Universitá degli Studi dell'Insubria, Varese, Italy.
Antimicrob Agents Chemother. 2010 Jun;54(6):2465-72. doi: 10.1128/AAC.00106-10. Epub 2010 Mar 22.
In glycopeptide-resistant enterococci and staphylococci, high-level resistance is achieved by replacing the C-terminal d-alanyl-d-alanine of lipid II with d-alanyl-d-lactate, thus reducing glycopeptide affinity for cell wall targets. Reorganization of the cell wall in these organisms is directed by the vanHAX gene cluster. Similar self-resistance mechanisms have been reported for glycopeptide-producing actinomycetes. We investigated glycopeptide resistance in Nonomuraea sp. ATCC 39727, the producer of the glycopeptide A40926, which is the precursor of the semisynthetic antibiotic dalbavancin, which is currently in phase III clinical trials. The MIC of Nonomuraea sp. ATCC 39727 toward A40926 during vegetative growth was 4 microg/ml, but this increased to ca. 20 microg/ml during A40926 production. vanHAX gene clusters were not detected in Nonomuraea sp. ATCC 39727 by Southern hybridization or by PCR with degenerate primers. However, the dbv gene cluster for A40926 production contains a gene, vanY (ORF7), potentially encoding an enzyme capable of removing the terminal d-Ala residue of pentapeptide peptidoglycan precursors. Analysis of UDP-linked peptidoglycan precursors in Nonomuraea sp. ATCC 39727 revealed the predominant presence of the tetrapeptide UDP-MurNAc-l-Ala-d-Glu-meso-Dap-d-Ala and only traces of the pentapeptide UDP-MurNAc-l-Ala-d-Glu-meso-Dap-d-Ala-d-Ala. This suggested a novel mechanism of glycopeptide resistance in Nonomuraea sp. ATCC 39727 that was based on the d,d-carboxypeptidase activity of vanY. Consistent with this, a vanY-null mutant of Nonomuraea sp. ATCC 39727 demonstrated a reduced level of glycopeptide resistance, without affecting A40926 productivity. Heterologous expression of vanY in a sensitive Streptomyces species, Streptomyces venezuelae, resulted in higher levels of glycopeptide resistance.
在糖肽耐药肠球菌和葡萄球菌中,通过用 d-丙氨酸-d-乳酸替代脂质 II 的 C 末端 d-丙氨酰-d-丙氨酸来实现高水平耐药,从而降低糖肽与细胞壁靶标的亲和力。这些生物体中的细胞壁重排由 vanHAX 基因簇指导。糖肽产生放线菌也报道了类似的自我耐药机制。我们研究了糖肽生产菌 Nonomuraea sp.ATCC 39727 的糖肽耐药性,该菌是糖肽 A40926 的产生菌,A40926 是半合成抗生素 dalbavancin 的前体,目前正在进行 III 期临床试验。在营养生长过程中,Nonomuraea sp.ATCC 39727 对 A40926 的 MIC 为 4μg/ml,但在 A40926 产生时增加到约 20μg/ml。Southern 杂交或用简并引物进行 PCR 均未在 Nonomuraea sp.ATCC 39727 中检测到 vanHAX 基因簇。然而,用于 A40926 生产的 dbv 基因簇包含一个基因 vanY(ORF7),可能编码一种能够去除五肽聚糖前体末端 d-Ala 残基的酶。对 Nonomuraea sp.ATCC 39727 中 UDP 连接的肽聚糖前体的分析表明,四肽 UDP-MurNAc-l-Ala-d-Glu-meso-Dap 和仅痕量的五肽 UDP-MurNAc-l-Ala-d-Glu-meso-Dap-d-Ala 占主导地位。这表明了 Nonomuraea sp.ATCC 39727 中一种新的糖肽耐药机制,该机制基于 vanY 的 d,d-羧肽酶活性。与此一致的是,Nonomuraea sp.ATCC 39727 的 vanY 缺失突变体表现出降低的糖肽耐药水平,而不影响 A40926 的生产力。vanY 在敏感链霉菌属物种 Streptomyces venezuelae 中的异源表达导致更高水平的糖肽耐药性。